NCT00136448View on ClinicalTrials.gov

High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 28, 1993

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions
Acute Myelogenous Leukemia
Interventions
DRUG

cytosine arabinoside (ara-C)

DRUG

daunomycin

DRUG

interleukin-2

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

lead

Dana-Farber Cancer Institute

OTHER